Perspectum launches new multiorgan imaging offering, Atlas®, for pharma sponsors at The Liver Meeting Digital Experience™ (TLMdX) 2020
- November 10, 2020
Boston, USA, November 10, 2020. Perspectum®, a leading imaging technology company and imaging CRO, elevates their service offering for clinical trials with the launch of Atlas for non-invasive, multi-organ characterization of disease.
As many as 1 in 4 Americans suffer from chronic liver disease and may experience clinical complications affecting other organs. Atlas is a rapid exam that can characterize multiple organs in a single, non-invasive MRI session.
Atlas offers solutions to key challenges in clinical trial operations and drug development including the scarcity of validated and objective biomarkers, heterogeneity of participant populations and the potential multi-organ involvement of diseases beyond the target intervention. The latter point is particularly relevant in the context of metabolic disease where interventions may improve characteristics across multiple systems.
Studies that currently utilize Atlas technology include MODIFY, a prospective 150-subject study to characterize multi-morbidity and evaluate clinical outcomes in patients with Type 2 Diabetes. COVERSCAN is a prospective study on 500 convalescent COVID-19 patients quantifying the impact of SARS-CoV-2 infection on multiple organ health and function.
“Findings from ongoing studies leveraging Atlas demonstrate the power of evaluating multiple organs at once. In the context of chronic liver diseases like NAFLD or NASH, sponsors can screen subjects for common disease characteristics to reduce screen fails, evaluate efficacy of target interventions, and identify new areas of investigation,” commented Dr. Vidyha Kumar, co-lead of Perspectum’s Pharma Solutions business.
--- Ends ---
Notes to editors
Atlas® is a metabolic imaging suite redefining multi-organ assessment for clinical trials in diabetes and metabolic disease. It provides quantitative metrics of health and function across multiple organs from a single, non-contrast MR scan. This product is for investigational use only.
Perspectum delivers cutting-edge digital technologies that help clinicians and pharmaceutical sponsors provide better care and accelerate development of therapeutics for patients with liver disease, diabetes, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients, clinicians and sponsors through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For more information, visit www.perspectum.com